Targeted Therapy Improves Pancreatic Cancer Survival
A recently approved drug that targets RAS proteins meaningfully improves outcomes for people with this difficult-to-treat cancer.
Progress Against Cancer
A recently approved drug that targets RAS proteins meaningfully improves outcomes for people with this difficult-to-treat cancer.
Sevabertinib received accelerated approval as first-line treatment for some lung cancers with HER2 activating mutations. The U.S. Food and Drug Administration (FDA) has granted accelerated approval to sevabertinib (Hyrnuo), for the treatment of adults...
In memory of those who lost their lives or families as a result of what happened on September 11, 2001, this edition of Cancer Research Catalyst reviews the effects of the attacks and showcases...
The FDA approves two therapies to treat rare blood cancers, and U.S. cervical cancer screening rates decline.
Recent reporting and rumors may have one believe that cigarettes are cool and popular again among young Americans. The data don’t bear this out—fewer young people smoke than ever—but a reminder of smoking’s dangers...
Ropeginterferon alfa-2b-njft treats essential thrombocythemia by targeting blood-forming cells in the bone marrow. The U.S. Food and Drug Administration (FDA) has approved ropeginterferon alfa-2b-njft (Besremi) injection to treat adults with a rare blood cancer,...
Cancer Research Catalyst has launched a new monthly series, “Unboxing Cancer News,” that highlights exciting cancer research discoveries. Read the first installment and learn about transmissible cancer in catfish, federal- vs. industry-sponsored trials, symptoms...
Therapy helps control excessive red blood cell production. The U.S. Food and Drug Administration (FDA) has approved rusfertide (Mimrylo) for adult patients with polycythemia vera, a rare, slow-growing blood cancer that causes excessive blood...
The FDA approves a RAS-targeted therapy, and government-funded research explores topics often neglected by industry trials.
Daraxonrasib is approved for previously treated or systemic-therapy-ineligible metastatic pancreatic adenocarcinoma. The U.S. Food and Drug Administration (FDA) has approved daraxonrasib (Rasonque) for adults with metastatic pancreatic adenocarcinoma whose cancer has progressed following at...
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More